CBIC extends concessional rate benefit to specified drugs used in COVID

The CBIC vide Notification No. 12/2021-Central Tax (Rate) dated September 30, 2021 has, further extended the duration of concessional rate benefit on specified drugs used in COVID treatment as well as further reduces GST rate on other specified drugs used in COVID treatment in order to adhere to the recommendations of 45th GST Council meeting held on September 17, 2021 as under:

A. Extension of existing concessional GST rates on following Covid-19 treatment drugs, up to December 31, 2021 from September 30, 2021, namely-

i. Amphotericin B – Nil

ii. Remdesivir – 5%

iii. Tocilizumab – Nil

iv. Heparin (anti-coagulant) – 5%

B. Further reduction of GST rate to 5% on other Covid-19 treatment drugs, valid up to December 31, 2021, namely-

i. Itolizumab

ii. Posaconazole

iii. Infliximab

iv. Favipiravir

v. Casirivimab & Imdevimab

vi 2-Deoxy-D-Glucose

vii. Bamlanivimab & Etesevimab

This notification shall come into force from the October 01, 2021 and remain in force December 31, 2021.

Source- https://www.cbic.gov.in/resources//htdocs-cbec/gst/notfctn-12-2021-cgst-rate.pdf